Consider switching to another disease-modifying therapy when unacceptable disease activity occurs in relapsing multiple sclerosis
- First Online:
- Cite this article as:
- Adis Medical Writers Drugs Ther Perspect (2014) 30: 141. doi:10.1007/s40267-013-0086-0
- 59 Downloads
Several disease-modifying therapies with distinct mechanisms of action are currently approved for the treatment of relapsing forms of multiple sclerosis. Switching to treatment with a different disease-modifying agent is a common approach when a patient experiences unacceptable breakthrough disease activity. Several practical points and suggestions for switching therapy in such patients are proposed.